Across the board, bleeding events are around 7-10% per the ELSO database. That includes head, GI, pulmonary, tamponade and cannula site bleeding. There is currently a TON of time and effort going into evaluating the best anticoagulation controls. Part of the problem is the 'standard' is the ACT, which is a crappy test. As TEGs and anti Xa levels become more available, and we better understand how to use those tests, bleeding events, blood product usage and heparin exposure should get better. I'm working on this for my fellowship project and have been to a couple of ELSO type meetings. Everyone is talking about it.
Part of what I want to do long term is bring ECMO to the adult world and understand who will benefit from it and when to use it.